Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Completed
GlaxoSmithKline
Phase 3
2008-11-01
This unblinded pilot study is intended to assess the feasibility of a larger double-blind,
randomized control trial. For the larger trial the investigators are interested in
understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors
for influenza infection in healthy adults, and in assessing the safety and tolerability of
seasonal antiviral prophylaxis in healthcare workers.
The pilot study will be assessing the rate of infection with influenza and the rate of
adherence to long-term zanamivir in 60 healthy volunteers.
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Completed
Mount Sinai Hospital, Canada
Phase 3
2008-11-01
This unblinded pilot study is intended to assess the feasibility of a larger double-blind,
randomized control trial. For the larger trial the investigators are interested in
understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors
for influenza infection in healthy adults, and in assessing the safety and tolerability of
seasonal antiviral prophylaxis in healthcare workers.
The pilot study will be assessing the rate of infection with influenza and the rate of
adherence to long-term zanamivir in 60 healthy volunteers.
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Completed
Fred Hutchinson Cancer Research Center
Phase 1/Phase 2
2009-03-01
The purpose of this study is to assess the safety and tolerability of triple combination
antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and
to gain data on the effectiveness of TCAD
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
